No Data
No Data
H.C. Wainwright Maintains Zymeworks(ZYME.US) With Hold Rating, Maintains Target Price $10
H.C. Wainwright analyst Robert Burns maintains $Zymeworks(ZYME.US)$ with a hold rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 24.0% and a
Zymeworks Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 17.1% HC Wainwright & Co. $10 → $10 Reiterates Buy → Buy 06/06/2024 17.1% HC Wainwright & Co. $
Zymeworks ZW171 IND for Mesothelin-expressing Cancers Cleared by FDA
Zymeworks Says FDA Clears Investigational New Drug Application for Cancer Therapy
Zymeworks (ZYME) said on Monday that the US Food and Drug Administration has cleared the investigational new drug application for its experimental therapy, ZW171, to treat mesothelin-expressing cancer
Market-Moving News for June 17th
BBY: 4% | UBS Upgrades Best Buy Co to Buy, Raises Price Target to $106ZYME: 13% | Zymeworks shares are trading higher after the FDA cleared the company's Investigational New Drug application for Zw171
Express News | Zymeworks Shares Are Trading Higher After the FDA Cleared the Company's Investigational New Drug Application for Zw171 for Mesothelin-expressing Cancers, With the Company Expecting to Initiate Clinical Development During 2024
No Data